aTYR PHARMA vs ImageneBio
ATYR and IMA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATYR and IMA compare
ImageneBio is the larger company, worth 2.6 times as much as aTYR PHARMA ($39.4M against $15.3M).
ImageneBio scores higher on the StockData Score (7 against 6 for aTYR PHARMA), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATYR | IMA |
|---|---|---|
| Size and price | ||
| Market cap | $15.3M | $39.4M |
| Share price | $6.11 | $3.47 |
| Change, 1 year | 745% | −59.4% |
| Change, 5 years | −98.1% | −98.1% |
| Beta (5Y) | – | 1.16 |
| Employees | 58 | 15 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.5× | 0.3× (better) |
| FCF yield | −286% | – |
| Growth | ||
| Revenue growth, 5Y average | −55.1% | −38.6% (better) |
| Profitability | ||
| Return on equity | −93.4% | −32.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.05 | 16.17 (better) |
| Altman Z-score | −17.17 | −1.10 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 54.9% |
| Held by insiders | 99.6% | 52.9% |
| Insider net buying, 12 months | $43.7K | $78.5K (better) |
| Short interest, % of float | 3302% | 0.86% |
Go deeper
- ATYR stock overview
- ATYR income statement
- ATYR valuation and score
- IMA stock overview
- IMA income statement
- IMA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.